

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Brilliant Violet 510(TM) anti-mouse CD19

RRID:AB_2562136

Type: Antibody

Proper Citation

BioLegend Cat# 115545, RRID:AB_2562136

Antibody Information

URL: http://antibodyregistry.org/AB_2562136

Proper Citation: BioLegend Cat# 115545, RRID:AB_2562136

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 6D5

Antibody ID: AB_2562136

Vendor: BioLegend

Catalog Number: 115545

Alternative Catalog Numbers: 115546

Record Creation Time: 20250820T015826+0000

Record Last Update: 20250820T122138+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse CD19.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kim H, et al. (2026) Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation. *Cell*.

Thurimella K, et al. (2026) Identifying microbial protease allergens through protein language model-guided homology. *Cell systems*, 17(3), 101510.

Li S, et al. (2026) The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection. *iScience*, 29(5), 115518.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. *Cancer immunology research*, 14(5), 771.

Li S, et al. (2025) Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. *Cancer immunology research*, 13(8), 1284.

Tang Z, et al. (2025) Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. *Cancer cell*, 43(6), 1025.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Li J, et al. (2025) Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. *Cell reports. Medicine*, 6(3), 101976.

Clarke D, et al. (2025) A vascular-associated fibroblastic cell controls pancreatic islet immunity. *Cell reports*, 44(9), 116189.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

Fang Q, et al. (2024) Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia. *Cell reports. Medicine*, 5(6), 101614.

Diehl C, et al. (2024) Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis. *Immunity*.

Ma B, et al. (2024) Protocol to examine immune subpopulations in murine conjunctiva and lacrimal gland using flow cytometry. *STAR protocols*, 5(1), 102921.

Bugno J, et al. (2024) Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4450.

Kaminski A, et al. (2023) Resident regulatory T cells reflect the immune history of individual lymph nodes. *Science immunology*, 8(89), eadj5789.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell reports. Medicine*, 4(11), 101244.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.

Edmunds GL, et al. (2022) Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization. *Communications biology*, 5(1), 9.

Sauter M, et al. (2022) Apolipoprotein E derived from CD11c+ cells ameliorates atherosclerosis. *iScience*, 25(1), 103677.